Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.2950 (-4.08%) ($5.2950 - $5.2950) on Tue. Jun. 1, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.13% (three month average) | RSI | 47 | Latest Price | $5.2950(-4.08%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.8% a day on average for past five trading days. | Weekly Trend | ADMS advances 0.6% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) KWEB(61%) ARKG(45%) EEM(45%) IBUY(44%) VWO(41%) | Factors Impacting ADMS price | ADMS will decline at least -2.065% in a week (0% probabilities). OIH(-28%) XOP(-26%) TBT(-26%) USO(-38%) XLE(-71%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.065% (StdDev 4.13%) | Hourly BBV | -0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.18(2.22%) | 10 Day Moving Average | $5.16(2.62%) | 20 Day Moving Average | $5.16(2.62%) | To recent high | -9.8% | To recent low | 5.7% | Market Cap | $150m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |